Hang Quach

Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

Jesus F San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji K Kumar, Meletios AA Dimopoulos, Thierry Facon, Maria-Victoria Mateos, Cyrille Touzeau, Andrzej J Jakubowiak, Saad Z Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, et al.

Journal article  |  2021  |  Blood

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progressio..

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Larysa Sanchez, Xavier Leleu, Jennifer L Beaumont, Hailin Yu, Stacie Hudgens, Maryana Simonova, Holger W Auner, Hang Quach, Sosana Delimpasi, Ivan Spicka, Ludek Pour, Iryna Kriachok, Meletios A Dimopoulos, Ganna Usenko, Roman Hajek, Reuben Benjamin, Dinesh Kumar Sinha, Christopher Venner, Thomas Illmer, Mamta Krishnan Garg, et al.

Journal article  |  2021  |  AMERICAN JOURNAL OF HEMATOLOGY

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryna Kriachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Mamta Garg, Don Ambrose Stevens, Hang Quach, et al.

Journal article  |  2021  |  AMERICAN JOURNAL OF HEMATOLOGY

In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor..

Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies

Chhay Lim, Priyadarshini Sinha, Simon J Harrison, Hang Quach, Monica A Slavin, Benjamin W Teh

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

INTRODUCTION: Treatment for multiple myeloma (MM) has continued to evolve with second generation immunomodulatory drugs (IMiDs), p..

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Stephen Boyle, Cameron Wellard, Elizabeth M Moore, Hilary Blacklock, Simon J Harrison, Phoebe Joy Ho, Jay Hocking, Zoe K McQuilten, Hang Quach, Ruth Spearing, Erica M Wood, Andrew Spencer, Peter Mollee

Journal article  |  2021  |  EUROPEAN JOURNAL OF HAEMATOLOGY

We read with interest the study from Rampotas et al (1) where they evaluated 158 transplant-non-eligible newly diagnosed myeloma p..

The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Hilary Blacklock, Simon J Harrison, P Joy Ho, Tracy King, Quach Hang, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

BACKGROUND: Real-world multiple myeloma (MM) data are scarce, with most data originating from clinical trials. The Myeloma and Rel..

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Meletios A Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Mamta Garg, Don Ambrose Stevens, Hang Quach, et al.

Journal article  |  2021  |  AMERICAN JOURNAL OF HEMATOLOGY

Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resultin..

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Hang Quach, Ajay Nooka, Olga Samoylova, Christopher P Venner, Kihyun Kim, Thierry Facon, Andrew Spencer, Saad Z Usmani, Sebastian Grosicki, Kenshi Suzuki, Sosana Delimpasi, Katja Weisel, Mihaela Obreja, Anita Zahlten-Kumeli, Maria-Victoria Mateos

Journal article  |  2021  |  BRITISH JOURNAL OF HAEMATOLOGY

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Gonzalez montes Yolanda, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf-Henrik Mellqvist, Roland Fenk, Hamdi Sati, Alexander Vorog, Richard J Labotka, Jichang Du, Mohamed Darif, Shaji Kumar

Journal article  |  2021  |  Journal of Clinical Oncology

8020 Background: MM patients (pts) often receive several lines of therapy with multiple drug combinations and, as lenalidomide (R..

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

Hang Quach, Masa Lasica, David Routledge, Anna Kalff, Andrew Lim, Michael Low, Jane A Estell, M Hasib Sidiqi, Philip Campbell, Richard Wilhelm Eek, Hock C Lai, Georgia J McCaughan, James D'Rozario, Peter Browlett, Rajeev Rajagopal, Jessica Heenan, Nicholas E Murphy, William Renwick, Georgina Huan, Peter Mollee

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

TPS8055 Background: Len maintenance post ASCT is standard of care for patients (pts) with NDMM. Deep responses (CR or better) pos..